Insmed Inc (INSM) Stock Price & Analysis
Insmed Inc (INSM) fell 0.46% to USD 106.92 as of July 25, 2026 at 03:09 UTC, according to Nexqual real-time market data.
INSM last closed at USD 107.41; the session ranged USD 105.77–108.18 on volume of 1,900,015 shares. Market capitalization is $23.18B, with a 52-week range of USD 90.39–212.75 (NMS). Source: Nexqual, July 25, 2026 at 03:09 UTC.
Key Statistics (as of July 25, 2026 at 03:09 UTC)
| Price | USD 106.92 |
|---|---|
| Change | ▼ 0.46% (down) |
| Previous Close | USD 107.41 |
| Open | USD 106.49 |
| Day Range | USD 105.77 – 108.18 |
| 52-Week Range | USD 90.39 – 212.75 |
| Volume | 1,900,015 shares |
| Market Cap | $23.18B |
| Exchange | NMS |
Technical Analysis (INSM)
Nexqual's technical model rates INSM "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:09 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.28 (neutral) |
| vs SMA50 | Above (USD 105.79) |
| MACD | 0.17 (positive) |
Analyst Ratings (INSM)
Wall Street analysts rate INSM "Strong Buy" based on 22 analysts, with a mean price target of USD 196.18 (range USD 140–243), per Nexqual as of July 25, 2026 at 03:09 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 22 |
| Mean Target | USD 196.18 |
| High Target | USD 243 |
| Low Target | USD 140 |
| Buy / Hold / Sell | 23 / 0 / 0 |
Earnings (INSM)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.68 |
| Revenue Estimate | $393.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.76 vs est -1 ▲ beat |
| 2025-12-31 | USD -1.54 vs est -1.17 ▼ miss |
| 2025-09-30 | USD -1.75 vs est -1.37 ▼ miss |
| 2025-06-30 | USD -1.7 vs est -1.31 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financials & Fundamentals (INSM)
| Total Revenue | $819.56M |
|---|---|
| Revenue Growth (YoY) | +229.60% |
| Gross Margin | +81.81% |
| Operating Margin | -65.46% |
| Profit Margin | -144.44% |
| ROE | -294.46% |
| Debt / Equity | 105.34 |
| Current Ratio | 4.47 |
| Total Cash | $1.22B |
| Total Debt | $742.46M |
| Free Cash Flow | $-606.20M |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financial Health Score (INSM)
Nexqual rates Insmed Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:09 UTC.
| Growth | Strong — Revenue +67% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 82%, operating -65% |
| Balance Sheet | Mixed — $1.22B cash vs $742M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$606M, burning cash |
| Efficiency | Critical — ROE -294%, ROA -31.1% |
Ownership (INSM)
| Insider Ownership | +0.52% |
|---|---|
| Institutional Ownership | +105.82% |
| Shares Outstanding | 216.75M |
| Float | 198.42M |
| Short % of Float | +8.34% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Leadership (INSM)
Insmed Inc is led by William H. Lewis (age 56), President, CEO & Chairman, per Nexqual as of July 25, 2026 at 03:09 UTC.
| President, CEO & Chairman | William H. Lewis (age 56) |
|---|---|
| Chief Financial Officer | Sara M. Bonstein (age 44) |
| Chief Operating Officer | Roger Adsett (age 56) |
| Chief Scientific Officer | Brian K. Kaspar (age 51) |
| Vice President of Investor Relations | Bryan Dunn |
Major Backers & Investors (INSM)
Notable institutional backers of Insmed Inc include JPMorgan, Darwin Global Management, Ltd., FMR, LLC, according to Nexqual as of July 25, 2026 at 03:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 16.77% |
| Darwin Global Management, Ltd. | 7.75% |
| FMR, LLC | 6.07% |
| Baker Bros. Advisors, LP | 3.42% |
| Artisan Partners Limited Partnership | 3.01% |
| Invesco | 3% |
| Shaw D.E. & Co., Inc. | 2.6% |
| GROWTH FUND OF AMERICA | 2.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.42% |
| BlackRock | 8.41% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
From Insmed Inc's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
- The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
- It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
- In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CYTK | Cytokinetics, Incorporated | USD 80.74 | ▼ 1.76% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 26.9 | ▼ 2.69% |
| PTCT | PTC Therapeutics, Inc. | USD 76.82 | ▼ 2.02% |
| HALO | Halozyme Therapeutics, Inc. | USD 81.93 | ▲ 5.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:09 UTC. This page is informational and not investment advice.